Jean‐François Baurain

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.4K citations

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski et al. · New England Journal of Medicine · 2021 · 806 citations · Full text

Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann et al. · Immunity · 1997 · 765 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Nk Inhibitory Receptor +8

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Martin J. van den Bent, Alba A. Brandes, R. Rampling et al. · Journal of Clinical Oncology · 2009 · 561 citations · Full text

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

Tisotumab Vedotin, Cervical Cancer, Metastatic Cervical Cancer +8